These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW. Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998 [Abstract] [Full Text] [Related]
27. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I. Br J Cancer; 2011 Mar 01; 104(5):863-70. PubMed ID: 21304524 [Abstract] [Full Text] [Related]
30. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis. Chen Y, Ren YL, Li N, Yi XF, Wang HY. Eur Rev Med Pharmacol Sci; 2016 May 01; 20(10):1974-85. PubMed ID: 27249595 [Abstract] [Full Text] [Related]
33. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X, Ju S. Pathol Oncol Res; 2018 Oct 01; 24(4):739-744. PubMed ID: 29520570 [Abstract] [Full Text] [Related]
36. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Gynecol Oncol; 2013 Oct 01; 131(1):52-8. PubMed ID: 23891789 [Abstract] [Full Text] [Related]